|
0
|
|
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations.
(academic.oup.com)
|
Belongia EA
…
Petrie JG
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#influenza
#immunogenicity
#observational
#efficacy
|
|
0
|
|
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial.
(academic.oup.com)
|
Konopnicki D
…
De Wit S
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#immunogenicity
#hiv
#immunocompromised
#seroconversion
|
|
0
|
|
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged >/=50 Years.
(academic.oup.com)
|
Goswami J
…
Das R
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#rna
#immunogenicity
#safety
#rsv
|
|
0
|
|
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
(academic.oup.com)
|
Brassington E
…
Hill A
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#cancer
#prevention
#immunogenicity
#hpv
|
|
0
|
|
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial.
(academic.oup.com)
|
Okumura N
…
Ujiie M
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#prophylaxis
#immunogenicity
#hiv
#mpox
|